Search Results

Haemonetics Corporation has completed its previously announced acquisition of OpSens Inc.

Haemonetics Corporation and OpSens, Inc. announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.

OpSens (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.

OpSens Inc. today reported its results for the first quarter of fiscal year 2022 ended November 30, 2021.

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary technology, is pleased to announce the successful treatment of 20 patients leading to the completion of the first in-man clinical study utilizing the SavvyWire.

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021, at 9:30 AM ET.

OpSens Inc. is pleased to announce the commencement of the human clinical study utilizing the SavvyWire, and successful treatment of the first patients.

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that Louis Laflamme, President and Chief Executive Officer will participate at the two following investment conferences.

OpSens Inc., a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, announced the appointment of Lori Chmura to its board of Directors, effective September 8.

OpSens Inc. announced today that it will present at two investment conferences.